Clinical and pharmacokinetic study of cefotetan in biliary tract infections: preliminary report.
Twelve hospitalised patients, affected by biliary tract infections, were treated with cefotetan at dosages ranging between 4 and 6 g daily i.v. In only 11 patients was the aetiological agent identified. Eleven patients (91.67%) completely recovered from their infections and the pathogens were eradicated; the treatment failed in only 1 patient (8.33%). Furthermore, determinations were made of cefotetan concentrations in serum, gallbladder bile, gallbladder wall and gallstones of 14 patients undergoing cholecystectomy: in 7 patients after only 1 injection i.v. of 2 g and in 7 patients after 7 injections i.v. of 2 g at intervals of 12 h. The levels recorded were several times higher than the minimum inhibitory concentrations against bacteria that are most often responsible for biliary infections. Cefotetan is a promising and effective antimicrobial agent in the therapy of biliary tract infections.
Cristiano
P
P
Institute of Internal Medicine, 1st Medical School, Naples University, Italy.
Lobello
R
R
Iovene
M R
MR
De Ascentis
G
G
Altucci
P
P
Paradisi
F
F
Manguso
L
L
D000328:Adult; D000368:Aged; D001424:Bacterial Infections / Q000188:drug therapy*; D001660:Biliary Tract Diseases / Q000188:drug therapy*; D015313:Cefotetan / Q000493:pharmacokinetics / Q000627:therapeutic use*; D002763:Cholecystectomy; D005260:Female; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D008875:Middle Aged
D015313:Cefotetan